COPD住院患者吸入制剂使用情况的调查分析及对策  

Investigation and analysis of the use of inhaled preparations in hospitalized patients with COPD

作　　者：蔡艳[1] 曹刚[1] 姜晓燕[1] 朱可[1] 唐艳芬[1] 杨水英[1] 吴育[1] 彭敏[1] Cai Yan;Cao Gang;Jiang Xiaoyan(The Traditional Chinese Medicine Hospital of Nantong City,Nantong,Jiangsu 226001)

机构地区：[1]南通市中医院,江苏南通226001

出　　处：《基层医学论坛》2020年第1期3-5,共3页The Medical Forum

基　　金：江苏省南通市卫生和计划生育委员会科研项目(WKZL2018037)

摘　　要：目的调查南通市中医院慢性阻塞性肺疾病(COPD)住院患者吸入制剂的使用情况,分析其合理性,并提出相应对策。为临床合理用药、合理配置医疗资源提供参考。方法回顾性调查2017年6月—2018年2月呼吸内科诊断为COPD的住院患者,统计患者基本资料,各吸入制剂的使用率,联用情况等信息。结果使用率最高的是噻托溴铵粉吸入剂,为31.35%,最低的是吸入用复方异丙托溴铵溶液,为3.78%。各吸入制剂的日均费用以噻托溴铵粉吸入剂最高,硫酸特布他林雾化液最低。各吸入制剂的DUI均小于1.0。治疗方案以ICS/LABA+LAMA为主。结论南通市中医院COPD住院患者吸入制剂用药总体较合理,但仍需改进,建议加强COPD诊疗规范,为患者制定个体化治疗方案。Objective To investigate the use of inhaled preparations in hospitalized patients with chronic obstructive pulmonary disease(COPD)in Nantong Traditional Chinese Medicine Hospital,analyze its rationality,and propose corresponding countermeasures.Provide reference for clinical rational use of drugs and rational allocation of medical resources.Methods A retrospective survey was conducted to investigate the inpatients diagnosed with COPD in the Department of Respiratory Medicine from June 2017 to February 2018.The basic data of the patients,the usage rate of each inhaled preparation,and the combined use were collected.Results The highest use rate was tiotropium bromide powder inhaler,which was 31.35%,and the lowest was inhaled compound ipratropium bromide solution,which was 3.78%.The daily average cost of each inhaled preparation was the highest in the inhalation of tiotropium bromide powder and the lowest in the atomized solution of terbutaline sulfate.The DUI of each inhaled formulation was less than 1.0 after calculation by the Drug Utilization Index(DUI).The treatment plan was mainly ICS/LABA+LAMA.Conclusions The inhalation preparations for inhaled preparations of patients with COPD in Nantong Traditional Chinese Medicine Hospital are generally reasonable,but they still need improvement.It is recommended to strengthen the standard of COPD diagnosis and treatment and develop individualized treatment plans for patients.

关 键 词：慢性阻塞性肺疾病 吸入制剂 用药分析 对策 

分 类 号：R56[医药卫生—呼吸系统]